For patients with chronic hepatitis C who undergo liver transplantation,recurrence of hepatitis C virus( HCV) infection after liver transplantation has always been a great challenge in the medical field. With our increased understanding of HCV replication cycle,the appearance of direct- acting antiviral agents( DAAs) has brought new hope to patients who have failed interferon therapy. Based on the latest research advances at home and abroad,this article retrospectively introduces the mechanism of action and the development of DAAs,focuses on the clinical application,therapeutic effects,and potential risks of various regimens with DAAs before and after liver transplantation,and systematically reviews the application of DAAs in the perioperative period of liver transplantation for patients with hepatitis C. The results show that DAAs are safe and effective as perioperative antiviral therapies,and a combination of drugs with different targets is recommended as the antiviral therapy in the perioperative period of liver transplantation for patients with chronic hepatitis C.